1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Google Scholar | Crossref | Medline2. The Global Cancer Observatory . IARC. Accessed May 2019. https://gco.iarc.fr/today/data/factsheets/populations/268-georgia-fact-sheets.pdf.
Google Scholar3. Jemal, A, Torre, L, Soerjomataram, I, Bray, F, eds. The Cancer Atlas. 3rd ed. American Cancer Society; 2019.
Google Scholar4. European School Survey Project on Alcohol and Other Drugs: Georgia Country Report . 2016. Tbilisi: National Centre for Disease Control and Public Health of the Ministry of Labour, Health and Social Affairs of Georgia.
Google Scholar5. Cancer Profile . Georgia. Accessed April 2018. https://www.moh.gov.ge/uploads/files/2018/Failebi/16.04.2018.pdf
Google Scholar6. NCDC . Cancer statistics. Accessed 2019. https://www.ncdc.ge/Pages/User/News.aspx?ID=bec659c0-56a2-4190-9c0c-e47a63bcca4f.
Google Scholar7. Walters, S, Maringe, C, Coleman, MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68:551-564.
Google Scholar | Crossref | Medline | ISI8. Kiladze, I, Mariamidze, E, Jeremic, B. Lung cancer in Georgia. J Thorac Oncol. 2020;15:1113-1118.
Google Scholar | Crossref | Medline9. Kiladze, I, Mariamidze, E, Baramidze, A, Lomidze, M, Meladze, K, Jeremic, B. Molecular profiling and characteristics of non-small-cell lung cancer patients in Georgia. Future Oncol. 2021;17:3585-3594.
Google Scholar | Crossref | Medline10. Ryska, A, Buiga, R, Fakirova, A, et al. Non-Small cell lung cancer in countries of Central and southeastern Europe: diagnostic procedures and treatment reimbursement surveyed by the Central European Cooperative Oncology Group. Oncologist. 2018;23:e152-e158.
Google Scholar | Crossref | Medline11. Soria, JC, Ohe, Y, Vansteenkiste, J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New Eng J Med. 2018;378:113-125.
Google Scholar | Crossref | Medline | ISI12. Scagliotti, GV, Parikh, P, von Pawel, J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
Google Scholar | Crossref | Medline | ISI13. Paz-Ares, L, de Marinis, F, Dediu, M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247-255.
Google Scholar | Medline | ISI14. Leora, H, Mansfield, A, Szczęsna, A, et al. First-Line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. New Eng J Med. 2018;379:2220-2229.
Google Scholar | Crossref | Medline15. Abdel Karim, N, Kelly, K. Role of targeted therapy and immune checkpoint blockers in advanced non-small cell lung cancer: a review. Oncologist. 2019;24:1270-1284.
Google Scholar | Crossref | Medline16. Zubizarreta, EH, Fidarova, E, Healy, B, Rosenblatt, E. Need for radiotherapy in low and middle income countries – the silent crisis continues. Clin Oncol. 2015;27:107-114.
Google Scholar | Crossref17. Jeremic, B, Classen, J, Bamberg, M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:119-130.
Google Scholar | Crossref | Medline | ISI18. Timmerman, RD, Herman, J, Cho, LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32:2847-2854.
Google Scholar | Crossref | Medline19. Patel, SH, Ma, Y, Wernicke, AG, Nori, D, Chao, KS, Parashar, B. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. Lung Cancer. 2014;84:156-160.
Google Scholar | Crossref | Medline20. Burdett, S, Rydzewska, L, Tierney, J, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10:CD002142.
Google Scholar | Crossref | Medline21. Bezjak, A, Temin, S, Franklin, G, et al. Definitive and adjuvant radiotherapy in locally advanced non–small-cell lung cancer: American Society of clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol. 2015;33:2100-2105.
Google Scholar | Crossref | Medline22. Jeremic, B, Casas, F, Dubinsky, P, Cihoric, N, Gomez-Caamano, A. The trimodality treatment approach in stage III/pN2 non-small cell lung cancer: “Usually Appropriate” may well be a very inappropriate treatment option. Am J Clin Oncol. 2015;38:645.
Google Scholar | Crossref | Medline23. Jeremić, B. Induction therapies plus surgery versus exclusive radiochemotherapy in stage IIIA/N2 non-small cell lung cancer (NSCLC). Am J Clin Oncol. 2018;41:267-273.
Google Scholar | Crossref | Medline24. Aupérin, A, Le Péchoux, C, Rolland, E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-2190.
Google Scholar | Crossref | Medline | ISI25. O'Rourke, N, Roqué I Figuls, M, Farré Bernadó, N, Macbeth, F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. Published online June 16, 2010. doi:10.1002/14651858.CD002140.pub3.
Google Scholar | Crossref26. Bradley, JD, Paulus, R, Komaki, R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-199.
Google Scholar | Medline | ISI27. Palma, DA, Olson, R, Harrow, S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051-2058.
Google Scholar | Crossref | Medline28. Gomez, DR, Tang, C, Zhang, J, et al. Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558-1565.
Google Scholar | Crossref | Medline29. Guckenberger, M, Lievens, Y, Bouma, AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18-e28.
Google Scholar | Crossref30. Dingemans, AC, Hendriks, LEL, Berghmans, T, et al. Definition of synchronous oligometastatic non-small cell lung Cancer-A consensus report. J Thorac Oncol. 2019;14:2109-2119.
Google Scholar | Crossref | Medline31. Jeremic, B . Timing of concurrent radiotherapy and chemotherapy in limited-disease small-cell lung cancer: “meta-analysis of meta-analyses.” Int J Radiat Oncol Biol Phys. 2006;64:981-982.
Google Scholar | Crossref | Medline32. Jeremic, B, Shibamoto, Y, Acimovic, L, Milisavljevic, S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 1997;15:893-900.
Google Scholar | Crossref | Medline33. Faivre-Finn, C, Snee, M, Ashcroft, L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116-1125.
Google Scholar | Crossref | Medline34. Aupérin, A, Arriagada, R, Pignon, JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. New Eng J Med. 1999;341:476-484.
Google Scholar | Crossref | Medline | ISI35. Le Péchoux, C, Dunant, A, Senan, S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10:467-474.
Google Scholar | Medline36. Jeremic, B, Shibamoto, Y, Nikolic, N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092-2099.
Google Scholar | Crossref | Medline37. Slotman, BJ, van Tinteren, H, Praag, JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36-42.
Google Scholar | Crossref | Medline38. Takahashi, T, Yamanaka, T, Seto, T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663-671.
Google Scholar | Crossref | Medline39. Slotman, B, Faivre-Finn, C, Kramer, G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. New Eng J Med. 2007;357:664-672.
Google Scholar | Crossref | Medline